FBInvestor
Stocks / Amylyx Pharmaceuticals Inc
Institutional Ownership

Amylyx Pharmaceuticals Inc

CUSIP 03237H101COMAMLXQ1 2026

13D / 13G Filings
46
Schedule 13D/13G on record
Beneficial Filers
17
Distinct reporting persons
Largest Stake
18.9%
Max % of class reported
Institutional Holders
165
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

46 filings · latest Feb 17, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 17, 2026Tcg Crossover Gp II, LLC13G/A11.0%6.24MSEC
2Feb 12, 2026Adage Capital Management, L.P.13G/A2.5%2.78MSEC
3Feb 5, 2026Fmr LLC13G/A15.0%16.47MSEC
4Jan 30, 2026The Vanguard Group13G5.3%5.80MSEC
5Jan 21, 2026Blackrock, Inc.13G/A7.1%7.78MSEC
6Nov 17, 2025Commodore Capital LP13G11.0%5.65MSEC
7Nov 14, 2025Perceptive Advisors LLC13G/A8.2%8.95MSEC
8Nov 14, 2025Point72 Asset Management, L.P.13G/A2.6%2.80MSEC
9Nov 13, 2025Adage Capital Management, L.P.13G/A6.4%6.82MSEC
10Oct 30, 2025The Vanguard Group13G/A4.9%5.27MSEC

36 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Amylyx Pharmaceuticals Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →